Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Jernej Kristl has worked on the following 20 EPO patent applications which have been published in the last five years:

EP12723210

BIOMARKERS FOR LUNG CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12730099

COMBINATION OF PANOBINOSTAT AND RUXOLITINIB IN THE TREATMENT OF CANCER SUCH AS A MYELOPROLIFERATIVE NEOPLASM

IPC classification:
A61K 31/4045, A61K 31/519
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12766990

PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN

IPC classification:
A61K 9/20, A61K 9/50, A61K 31/436
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12787709

COMBINATION OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND A MODULATOR OF THE JANUS KINASE 2-SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5 PATHWAY

IPC classification:
A61K 31/436, A61K 31/437, A61K 31/5377, A61K 45/06, A61P 35/00, A61P 35/04
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14164259

Combination of a rapamycin derivative and letrozole for treating breast cancer

IPC classification:
A61K 31/337, A61K 31/4196, A61K 31/436, A61K 31/502, A61K 31/704, A61K 31/7068, A61K 33/24, A61P 35/00
Applicant:
Novartis AG
Applicant:
Novartis Pharma GmbH
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14164565

Treatment of solid brain tumours with a rapamycin derivative

IPC classification:
A61K 31/436, A61P 35/00
Applicant:
Novartis AG
Applicant:
Novartis Pharma GmbH
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP13707527

CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13721886

BIOMARKERS FOR IAP INHIBITOR THERAPY

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP11790916

CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION

IPC classification:
A61K 31/495, A61P 35/00, C07D 401/12
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14717202

PHARMACEUTICAL COMPOSITIONS COMPRISING EVEROLIMUS

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/28, A61K 31/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP14741382

MODIFIED RELEASE FORMULATION

IPC classification:
A61K 9/20, A61K 31/4439
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP12703670

METHODS OF USING ALK INHIBITORS

IPC classification:
A61K 31/00, A61K 31/506, A61P 35/00, C07D 401/12, C07D 401/14
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
PATENT GRANTED
EP15188988

COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS

IPC classification:
A61K 31/506, A61P 25/00, A61P 31/00, A61P 37/00, C07D 213/74, C07D 239/48, C07D 239/95, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 413/12, C07D 417/12, C07D 451/02, C07D 453/02, C07D 471/04, C07D 473/16, C07D 487/04, C07D 487/08
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14732980

ALKYLATION WITH AN ALKYL FLUOROALKYL SULFONATE

IPC classification:
A61K 31/436, C07C 303/28, C07D 498/18
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14766301

COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES

IPC classification:
A61K 31/506, A61K 31/519, A61K 45/00, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP16186041

A RAPAMYCIN DERIVATIVE FOR TREATING LUNG CANCER

IPC classification:
A61K 31/436, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
APPLICATION PUBLISHED
EP15727470

CERITINIB FORMULATION

IPC classification:
A61K 9/20, A61K 31/435
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15744702

TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE

IPC classification:
A61J 3/06, A61J 3/10, A61K 31/4985, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
EXAMINATION REQUESTED
EP15824774

COMBINATION THERAPY

IPC classification:
A61K 31/198, A61K 31/4985, A61K 31/505, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
EXAMINATION REQUESTED
EP15767682

COMBINATION THERAPIES OF ALK INHIBITORS

IPC classification:
A61K 31/506, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Jernej Kristl, Novartis AG
Status:
Request for examination was made

Please Sign in to use this feature